Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Wilms Tumor: early-phase trial registry
9 of 15 indexed Wilms Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 9 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Wilms Tumor: 15 US clinical trials tracked, 9 recruiting.
Wilms Tumor is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 4 of these trials.
Enrollment posture brief
Registry condition wilms-tumor
OPEN 9 | RECR 60% | LATE 0 | EARLY 13 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Wilms Tumor lists 9 open slots (60% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Wilms Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Wilms Tumor is recruiting above its size-band peers.
9 of 15 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Wilms Tumor research.
Baylor College of Medicine accounts for 4 of 15 trials (26.7%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Wilms Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 28 among the 15 trials that report a genuine target (sentinel values excluded). 12 of those (80%) plan for fewer than 100 participants.
-
Wilms Tumor research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
International PPB/DICER1 Registry
Children's Hospitals and Clinics of Minnesota
NCT03382158
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
St. Jude Children's Research Hospital
NCT04968990
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05985161
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT04897321
Pencil Beam Scanning in Patients With Renal Tumors
Children's Hospital of Philadelphia
NCT03810651
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04715191
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
NCT06198296
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT07148050
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Children's National Research Institute
NCT07172958
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04377932
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT05103631
iCAT for Recurrent/Refractory/HR Solid Tumors
Dana-Farber Cancer Institute
NCT01853345
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Timothy Cripe
NCT00931931
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Wilms Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Wilms Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Wilms Tumor page
15 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Wilms Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Wilms Tumor trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Wilms Tumor condition card totals 15 registered trials; most-linked intervention HSV1716; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.